

XI Conferencia Bienal *11th Biennial Conference*
Barcelona – Pittsburgh

World Trade Center (Barcelona)

23 – 25 May 2018



ACE - UIC
barcelona

In collaboration with
GRIFOLS





In collaboration with

GRIFOLS

Araclon Biotech

GRIFOLS



SOCIETAT CATALANA DE
GERIATRIA I GERONTOLOGIA


FUNDACIÓ
CASTELL DE PERALADA

PEIX a CASA
Una experiència diferent de comprar peix.



II Symposium on Dementia Genetics

CIBERNED - Dementia Genetics Spanish Consortium (DEGESCO)

Miércoles, 23 de Mayo / Wednesday, May 23

08:30 – 09:00 **Acreditación / Registration**

09:00 – 10:00 **Mesa 1 / Panel 1 - Genetics of AD.**

Moderador / Chair: **Jordi Clarimón**, Hospital de Sant Pau, Barcelona.

09:00 – 09:20 Rare variants in Early onset in AD. Update of the ongoing ISCIII project.

Pascual Sánchez-Juan. HU. Marqués de Valdecilla. University of Cantabria, Santander.

09:20 – 09:40 European Alzheimer's disease Biobank. An update.

Jean Charles Lambert. Institut Pasteur (Lille).

09:40 – 10:00 Advances in Genetics and Epigenetics of AD. Alzheimer's disease Sequencing Program.

Sudha Seshadri. Boston University. Alzheimer's disease Center.

10:00 – 10:30 **Pausa Café / Coffee Break**

11:00 – 11:30 **Inauguración / Official opening**

With the participation of Fundació Bancària "la Caixa", Grifols, Fundació ACE and Fundación Reina Sofía representatives.

11:30 – 12:30 **Mesa 2 / Panel 2 - GR@ACE/DEGESCO GWAS project. Results obtained in stage I.**

Moderadores / Chairs: TBC, **Mercè Boada**, Fundació ACE. Barcelona

11:30 – 12:00 Design and implementation of the Spanish Biobank / GWAS array.

Ángel Carracedo. Director del Centro Nacional de Genotipado. Santiago de Compostela.

12:00 – 12:30 GR@ACE project Stage I. Results.

Agustín Ruiz. Fundació ACE. Barcelona.

12:30 – 14:00 **Mesa 3 / Panel 3 - Beyond GWAS: understanding the biology behind genetics findings.**

Moderadores / Chairs: **Alfredo Ramírez**, University of Cologne, **Manel Esteller**, IDIBELL – Bellvitge Biomedical Research Institute, Barcelona.

12:30 – 13:00 Epigenetic dysregulation within the brainstem in the development and course of Alzheimer's disease.

Daniel van den Hove, Maastricht University.

13:00 – 13:30 The effect of common variants above and beyond APOE on the age at onset of Alzheimer's disease.

Sven van der Lee, VUMC Amsterdam.

13:30 – 14:00 BDNF Val66Met polymorphism moderates the effect of Alzheimer pathology on hippocampal network connectivity.

Michael Ewers, ISD, Klinikum der Universität München.

14:00 **Lunch**



Intensive Workshop on ETHICS

Miércoles, 23 de Mayo / Wednesday, May 23

14:00 – 15:30 **Acreditación / Registration**

15:30 – 18:30 **TALLER DE ÉTICA / WORKSHOP ON ETHICS**

15:30 – 15:40 **Welcome and objectives**

By: **Mercè Boada**, *Fundació ACE, Barcelona*, **Frank Jessen**, *University of Cologne. PreDADQoL Study.*

15:40 – 16:35 **Mesa / Panel – Predictive Diagnosis of Alzheimer's disease: Quality of Life of Individuals at Risk and their Close Other (PreDADQoL).**

Moderadores / Chairs: **Núria Terribas**, *Director of Fundació Víctor Grifols i Lucas*, **Christiane Woopen**, *Cologne Center for Ethics, Rights, Economics, and Social Sciences of Health- CERES. University of Cologne. PreDADQoL Study.*

15:40 – 16:05 Ethics and Alzheimer's: what is changing
Núria Terribas, *Director of Fundació Víctor Grifols i Lucas.*

16:05 – 16:20 Effects of biomarker-based dementia risk disclosure in patients with MCI – Design of the clinical subproject in the PreDADQoL study.
Ayda Rostamzadeh, *University of Cologne.*

16:20 – 16:35 Expectations of MCI patients and their caregivers towards biomarker-based predictive AD diagnosis – Preliminary findings from the PreDADQoL study.
Carolin Schwegler, *Cologne Center for Ethics, Rights, Economics, and Social Sciences of Health- CERES. University of Cologne. PreDADQoL Study.*

16:35 – 17:35 **Mesa / Panel – How to manage disclosures using biomarkers?**

Moderadores / Chairs: **Frank Jessen**, *University of Cologne*, **Mercè Boada**, *Fundació ACE, Barcelona*

16:35 – 16:55 Cerebrospinal fluid (CSF) biomarkers.
Albert Lleó, *Unitat de Demències Hospital Sant Pau (Barcelona).*

16:55 – 17:15 Positron emission tomography (PET) imaging.
Jennifer Lingler, *Department of Health and Community Systems, University of Pittsburgh.*

17:15 – 17:35 Disclosure of APOE Genotype and Risk of Alzheimer's disease.
Scott Roberts, *Genomics, Health & Society Program, Center for Bioethics and Social Sciences in Medicine, University of Michigan.*

17:35 – 17:50 **Pausa Caf  / Coffee Break**


17:50 – 18:30 **Debate / Discussion**

Moderador / Chair: **Bj rn Schmitz-Luhn**, *PreDADQoL project, University of Cologne.*

Albert Lle  *Unitat de Dem ncies. Hospital Sant Pau, Barcelona*
Jennifer Lingler *Department of Health and Community Systems, University of Pittsburgh*
Scott Roberts *Genomics, Health & Society Program, Center for Bioethics and Social Sciences in Medicine, University of Michigan.*

Christiane Woopen *Cologne Center for Ethics, Rights, Economics, and Social Sciences of Health- CERES. University of Cologne. PreDADQoL Study.*

Silvia Gil *Fundaci  ACE, Barcelona. PreDADQoL Study.*
Frank Jessen *University of Cologne. PreDADQoL.*



Jueves, 24 de Mayo / Thursday, May 23

07:30 – 08:30 **Acreditación / Registration**

08:30 – 09:00 **Hot topic lecture - Challenges and Progress in Imaging Proteinopathies.**

By **Chester Mathis**, *University of Pittsburgh*

Moderador / Chair: **Gemma Monté**, *Fundació ACE, Barcelona*

09:00 – 10:00 **Mesa / Panel - Neuroimagen / Neuroimaging**

Moderadores / Chairs: **Chester Mathis**, *University of Pittsburgh*, **Gemma Monté**, *Fundació ACE, Barcelona*

09:00 – 09:20 Perplexes of current Tau PET imaging: importance of neuropathology validation.
Milos Ikonovic, *University of Pittsburgh*.

09:20 – 09:40 Analysis of anatomical MRI using SPM.
John Ashburner, *Wellcome Trust Centre for Neuroimaging, University College London*.

09:40 – 10:00 Two-year longitudinal monitoring of amnesic mild cognitive impairment patients with prodromal Alzheimer's disease using topographical biomarkers derived from resting state fMRI.
Jorge Jovicich, *Università degli Studi di Trento*.

10:00 – 10:15 **Pausa Café / Coffee Break**

10:15 – 10:45 **Hot topic lecture - Use of amyloid imaging in clinical trials and for the validation of fluid Biomarkers.**

By **Victor Villemagne**, *University of Melbourne*

Moderador / Chair: **Pedro Pesini**, *Araclon*.

10:45 – 11:45 **Mesa / Panel – Biomarcadores / Biomarkers**

Moderadores / Chairs: **Victor Villemagne**, *University of Melbourne*, **Pedro Pesini**, *Araclon*

10:45 – 11:05 Albumin functionality in Alzheimer Disease.
Montserrat Costa, *Grifols, Barcelona*

11:05 – 11:25 Omics approximation in the study of CSF in AD patients.
Gerard Piñol, *Hospital Universitari de Santa Maria, Lleida / Universitat de Lleida*

11:25 – 11:45 Novel Insights into the Functional Plasma Proteome in Alzheimer's disease.
Steven Braithwaite, *Alkahest, San Carlos, CA*

11:45 – 12:45 **Inauguración / Official Opening**

V Premio "Fundació ACE. Joan Boada & Mercè Rovira" / 5th "Fundació ACE. Joan Boada & Mercè Rovira" award

Presentado por: / Introduced by: **Lluís Tárraga**, *Fundació ACE, Barcelona*

12:45 – 13:15 **Hot topic lecture - Explorations in the aging human connectome.**

By **James T. Becker**, *University of Pittsburgh*

Moderador / Chair: **Lluís Tárraga**, *Fundació ACE, Barcelona*

13:45 – 14:45 **Almuerzo / Lunch**

15:00 – 15:30 **Hot topic lecture - Epigenomics of Dementia.**

By **Manel Esteller**, *IDIBELL – Bellvitge Biomedical Research Institute, Barcelona*

Moderador / Chair: **Agustín Ruiz**, *Fundació ACE, Barcelona*



15:30 – 16:30

Mesa / Panel – Avances en genética / Advances in genomics.

Moderadores / Chairs: **Manel Esteller**, IDIBELL – *Bellvitge Biomedical Research Institute, Barcelona*, **Agustín Ruiz**, *Fundació ACE, Barcelona*.

15:30 – 15:50 How Can we Accelerate Dementia Prevention and Treatment? Population Neuroscience and Personalized Care.
Sudha Seshadri, *Boston University. Alzheimer's disease Center*.

15:50 – 16:10 Exploring biological consequences of genetic risk factors for Alzheimer's disease.
Alfredo Ramírez, *University of Cologne*.

16:10 – 16:30 Genetic risk for schizophrenia and psychosis in Alzheimer disease.
Robert Sweet, *Psychiatry Dept. University of Pittsburgh*.

16:30 – 17:00

Hot topic lecture - Innovative strategies in AD.

By **Norman Relkin**, *Weill Cornell Medical College (TBC)*
Moderador / Chair: **Mercè Boada**, *Fundació ACE, Barcelona*.

17:00 – 18:00

Mesa / Panel – Innovative Strategies 1.

Moderadores / Chairs: **Norman Relkin**, *Weill Cornell Medical College*, **Mercè Boada**, *Fundació ACE, Barcelona*.

17:00 – 17:15 Update on the clinical development of ABvac40, an active immunotherapy against Alzheimer's disease.
Pedro Pesini, *Araclon*.

17:15 – 17:30 Título/Title: *TBD* Recambio plasmático en EA / *Plasma Exchange in AD*.
Antonio Páez, *Grifols*.

17:30 – 17:45 Aducanumab 36-Month Data from the PRIME Study: A Randomized, Double-Blind, Placebo-Controlled Phase 1b Study in Patients with Prodromal or Mild Alzheimer's disease.
Carmen Castrillo-Viguera, *Clinical Development AD, Biogen*.

17:45 – 18:00 Disease modifying combination therapy in next generation clinical trials.
Adam Fleisher, *Lilly*.

18:00 – 18:15

Pausa Café / Coffee Break

18:15 – 19:00

Mesa / Panel – Innovative Strategies 2

Moderador / Chair: **Isabel Hernández** *Fundació ACE*, **Carla Abdelnour**, *Fundació ACE, Barcelona*

18:15 – 18:30 Lilly BACE Inhibitor Program and Early Phase Pipeline.
Cynthia Duggan, *Lilly*.


18:30 – 18:45 Roche in Alzheimer's disease - Current developments.
Vera Zingler, *Alzheimer's Disease Global Medical Team Leader Crenezumab, Roche*.

18:45 – 19:00 Título/Title: *TBD*
Ponente / Speaker: **Olga Sánchez**, *ABBVIE*.

19:00 – 19:30

Hot topic lecture – Present and future of CSF biomarkers.

By **Charlotte Teunissen**, *VU University Medical Center*.
Moderador / Chair: **Adela Orellana**, *Fundació ACE, Barcelona*.



- 08:30 – 09:00** **Hot topic lecture - The long term prediction of incident dementia by commonly used biomarkers: amyloid deposition, neurodegeneration and vascular disease.**
By **Oscar López**, *University of Pittsburgh*.
Moderador / Chair: **Marta Marquié**, *Fundació ACE, Barcelona*.
- 09:00 – 10:00** **Mesa / Panel – Cohortes españolas / Spanish cohorts**
Moderadores / Chairs: **Óscar López**, *University of Pittsburgh*, **Marta Marquié**, *Fundació ACE, Barcelona*
- 09:00 – 09:15 FACEHBI: Fundació ACE Healthy Brain Initiative for the study of cognition and biomarkers in individuals with Subjective Cognitive Decline.
Gemma Monté, *Fundació ACE, Barcelona*
- 09:15 – 09:30 The Vallecas Project: Predicting future development of mild cognitive impairment in the cognitively healthy elderly.
Bryan Strange, *Director, Dep. Neuroimagen del Centro de Enfermedad de Alzheimer, Fundación Reina Sofía-CIEN, Madrid, Spain*.
- 09:30 – 09:45 Proyecto Gipuzkoa Alzheimer; estudio Deba; programa GOIZ-Beasain.
Mikel Tainta, *Center for Research and Advanced Therapies, Fundación CITA-alzheimer Fundazioa, Donostia/San Sebastian*.
- 09:45 – 10:00 The ALFA Study. First results in a middle-aged cognitively healthy cohort.
Gonzalo Sánchez Benavides, *Fundación Pasqual Maragall*.
- 10:00 – 10:30** **Hot topic lecture - Subjective Cognitive Decline: a new scope.**
By **Frank Jessen**, *University of Cologne*.
Moderador / Chair: **Octavio Rodríguez**, *Fundació ACE, Barcelona*.
- 10:30 – 11:00** **Pausa Café / Coffee Break**
- 11:00 – 12:00** **Mesa / Panel – Predicción y prevención / Prediction and prevention.**
Moderadores / Chairs: **Frank Jessen**, *University of Cologne*, **Octavio Rodríguez** *Fundació ACE, Fundació ACE, Barcelona*.
- 11:00 – 11:15 Models of Patient Engagement for Alzheimer's Disease (MOPEAD): estrategias para el diagnóstico precoz en la comunidad.
Octavio Rodríguez, *Fundació ACE, Barcelona*.
- 11:15– 11: 30 Does the prevalence of MCI decline? Evidence from a prospective, population-based longitudinal study with a follow-up of 25 years.
Johannes Schroeder, *Universidad de Heilderberg*.
- 11:30 – 11:45 Using PET imaging to study Alzheimer's disease pathology: A Role for Lifestyle?
Annie Cohen, *University of Pittsburgh*.
- 11:45 - 12:00 Sustaining Brain Health and Promoting Resilience to Prevent Dementia.
Álvaro Pascual-Leone, *Harvard Medical School, Boston & Institut Guttmann, Barcelona*.
- 12:00 – 12:30** **Hot topic lecture- Presymptomatic brain changes in familial Alzheimer's disease: implications for prevention trials.**
By **Yakeel T. Quiroz**, *Director, Familial Dementia Neuroimaging Lab, Massachusetts General Hospital, Boston*.
Moderador / Chair: **Marcelo Berthier**, *Fundació ACE, Barcelona*.



Viernes, 25 de Mayo / Friday, May 25

12:30 – 13:00

Mesa / Panel – New approaches on neuropsychology

Moderadores / Chairs: **Marcelo Berthier**, Universidad de Málaga, **Montse Alegret**, Fundació ACE, Barcelona

12:30 – 12:40 Cambios cerebrales adaptativos o compensatorios en la organización del lenguaje en el envejecimiento.

Marcelo Berthier, Universidad de Málaga

12:40 – 12:50 The Spanish version of Face-Name Associative Memory Exam (S-FNAME) performance is related to brain amyloid burden in Subjective Cognitive Decline

Montserrat Alegret, Fundació ACE, Barcelona

12:50 – 13:00 Accelerated long-term forgetting in asymptomatic individuals at risk of familial and sporadic Alzheimer's disease.

Chris Butler, Nuffield Department of Clinical Neurosciences. Oxford University.

13:00 – 13:30

Conclusiones finales y escenario futuro / Final remarks and future scope

Chairs: **Mercè Boada** Fundació ACE, Barcelona, **Agustín Ruiz**, Fundació ACE, Barcelona.

Oscar Lopez

University of Pittsburgh, Scientific Committee of Fundació ACE.

Jesús Ávila

Centro de Biología Molecular Severo Ochoa, Madrid. Scientific Committee of Fundació ACE.

James Becker

University of Pittsburgh. Scientific Committee of Fundació ACE.

Chet Mathis

University of Pittsburgh. Scientific Committee of Fundació ACE.

13:30 – 13:45

Clausura / Closing Ceremony

By **Lluís Tárraga**, Fundació ACE, Barcelona and **Xavier Corbella**, Vicedecano, Facultat de Medicina de la Universitat Internacional de Catalunya.

